Stocks making the biggest moves premarket: CF Industries, EchoStar, KB Home & more

CF Industries slid nearly 4% as reports on U.S.-Iran war negotiations suggested fertilizer shortages could ease after gains of >27% since the Strait of Hormuz closure. Arm rose ~13% after unveiling its first in-house chip and projecting $15B revenue by 2031; EchoStar jumped ~7% on reports SpaceX may file for an IPO (EchoStar holds ~3% stake). KB Home missed Q1 estimates with EPS $0.52 vs $0.55 and revenue $1.08B vs $1.10B and cut near-term delivery/revenue outlook; Braze beat Q4 revenue $205.2M vs $198.2M and raised guidance but missed adj. EPS at $0.10 vs $0.14. Merck agreed to buy Terns at $53/sh in cash, valuing it at $6.7B (≈6% premium), deal expected to close in Q2.

Analysis

The CF move is primarily a geopolitics-to-commodities flow trade; if shipping through the Strait of Hormuz reopens or sanctions/escrow deals reduce perceived tail risk, urea/ammonia front-month curves can compress 20-40% in weeks, crushing margins for vertically integrated producers that priced in scarcer capacity. Second-order: cheaper fertilizer would accelerate fertilizer application ahead of the Northern Hemisphere planting season, boosting short-cycle crop yields and pressuring ag-inputs and logistics volumes (rail, ports) within one to two quarters.

ARM’s pivot to in-house silicon is a structural pivot in the IP market: if ARM converts even 10-15% of its licensing clients to product customers over 2–3 years it shifts revenue mix toward higher-margin recurring OEM sales but increases capex/ops risk and potential channel conflict with existing licensees. For EchoStar, a staged monetization of a SpaceX stake would likely be realized via secondary sales post-IPO rather than a single block sale, implying multi-month liquidity events that can re-rate SATS asymmetrically versus peer satcom equities.

KB Home’s miss and weak deliveries keep downside convexity in housing equities — cancellations and incentives typically lag initial guidance by one quarter and then accelerate, so expect more negative revisions over 3–6 months. Braze’s top-line beat with EPS miss suggests growth at the expense of margin; if guidance holds the stock can rerate but it’s vulnerable to any slip in gross margin or higher-than-forecast S&M. Terns (Merck bid) is a classic near-term merger arbitrage with regulatory and scientific readout tail risks until close in Q2.

Key Decisions for Investors

• Short CF via a 1–3 month put spread (caps cost, captures near-term reversal if Iran negotiations advance). Trade size: tactical (<=1% NAV). Reward: 15–30% downside capture if fertilizer curves compress; Risk: talks stall/flare → rapid squeeze.
• Long ARM via a 3–6 month call spread to play de-risked product commercialization (buy-to-unwind on incremental OEM announcements). Position <=2% NAV. Target 2:1 reward/risk if company prints progressive product revenue cadence; downside if execution or channel pushback emerges.
• Long SATS (EchoStar) using a 3-month call spread to play SpaceX IPO filing speculation and potential staged stake monetization. Size 0.5–1% NAV. Expected payoff: 30–100% on filing/confirmation; risk of no filing → premium decay.
• Short KBH outright or via a 3-month put (directional) and hedge by going long a better-capitalized builder or the HYG/IG credit protection to offset systemic housing risk. Target 15–30% downside within 3–6 months if delivery revisions continue; risk is faster-than-expected mortgage rate relief.
• Merger arbitrage: buy TERN at the current spread to $53 with an expected close in Q2. Position size conservative (<=1% NAV) given regulatory risk. Expected return: single-digit percent annualized if spread is small; downside >30% if deal collapses — size accordingly and use stop-loss discipline.